Lyme disease remains the most common vector-borne illness in the Northern Hemisphere. In the United States alone, an estimated ~476,000 people are diagnosed and treated each year, with an additional ~132,000 cases reported annually in Europe in countries with surveillance systems. The geographic footprint of Lyme disease continues to expand, and early symptoms — such as rash, fatigue, fever, or joint pain — are often missed or misinterpreted, allowing disease to progress and, in some cases, lead to serious complications involving the joints, heart, or nervous system. There is currently no approved human vaccine for Lyme disease, underscoring the significant unmet medical need and the importance of continued scientific progress in this space. The Global Lyme Vaccine Lead secondee will play a pivotal role in shaping and executing the global strategy, launch planning, launch execution and lifecycle development for the Lyme disease vaccine (PYS ~$1B) during a pivotal time (L-1) for the asset. They will partner closely with cross-functional and regional stakeholders – Regulatory, Clinical, GAV, Medical Affairs, and both US and ICO teams – to enable strong Local execution. This leader will bring a combination of strong commercial acumen, strategic thinking, and ability to operate in a highly dynamic, pre-launch environment. Success in this role will require influencing and navigating ambiguity, fostering alignment across diverse stakeholders, and ability to thrive in a fast-paced environment.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Number of Employees
5,001-10,000 employees